AzTrials
AzTrials

Acute Lymphoblastic Leukemia (ALL)Phase 2NCT02259348

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

A Phase 2 study testing Cyclophosphamide, Fludarabine and G-CSF in people with Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML), run by St. Jude Children's Research Hospital at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record

Search all trials

Trial summary

This pilot phase II trial studies how well a new reduced intensity conditioning regimen that includes haploidentical donor NK cells followed by the infusion of selectively T-cell depleted progenitor cell grafts work in treating younger patients with hematologic malignancies that have returned after or did not respond… Read more about this study

Who is it for?
Ages Up to 21 years
What is being tested?
Cyclophosphamide, Fludarabine and G-CSF
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
12 participants
Where
1 siteUnited States
Study dates
Oct 2014to Mar 2016
Phase
Phase 2

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 21 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Age less than or equal to 21 years.
  • One of the following hematologic malignancies that has relapsed or remains refractory after prior allogeneic hematopoietic cell transplant (HCT):
  • ALL, AML, Myeloid Sarcoma, CML, Juvenile myelomonocytic leukemia (JMML), myelodysplastic syndrome (MDS), non-Hodgkin lymphoma (NHL)
  • Has a suitable single haplotype matched (≥ 3 of 6) family member donor.
  • Does not have any other active malignancy other than the one for which this transplant is indicated.
  • If prior central nervous system (CNS) leukemia, it must be treated and in CNS complete remission (CR)
Show all 24Show fewer
  • Does not have current uncontrolled bacterial, fungal, or viral infection.
  • Patient must fulfill pre-transplant evaluation:
  • Left ventricular ejection fraction > 40%, or shortening fraction ≥ 25%.
  • Creatinine clearance (CrCl) or glomerular filtration rate (GFR) ≥ 50 ml/min/1.73m2.
  • Forced vital capacity (FVC) ≥ 40% of predicted value; or pulse oximetry ≥ 92% on room air if patient is unable to perform pulmonary function testing.
  • Karnofsky or Lansky (age-dependent) performance score ≥ 50 (See Appendix A).
  • Bilirubin ≤ 3 times the upper limit of normal for age.
  • Alanine aminotransferase (ALT) ≤ 5 times the upper limit of normal for age.
  • Not pregnant. If female with child bearing potential, must be confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment.
  • Not breast feeding
  • DONOR: At least single haplotype matched (≥ 3 of 6) family member
  • DONOR: At least 18 years of age.
  • DONOR: HIV negative.
  • DONOR: Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female).
  • DONOR: Not breast feeding.
  • DONOR: Regarding donation eligibility, is identified as either:
  • Completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance; OR
  • Does not meet 21 CFR 1271 eligibility requirements, but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271.

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105

Other trials in United States

About this study

Official title: CD45A-Depleted Haploidentical Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

This pilot phase II trial studies how well a new reduced intensity conditioning regimen that includes haploidentical donor NK cells followed by the infusion of selectively T-cell depleted progenitor cell grafts work in treating younger patients with hematologic malignancies that have returned after or did not respond to treatment with a prior transplant. Giving chemotherapy and natural killer cells before a donor progenitor cell transplant may help stop the growth of cells in the bone marrow, including normal blood-forming cells (progenitor cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's cells. When the healthy progenitor cells from a related donor are infused into the patient they make red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Removing specific T cells from the donor cells before the transplant may prevent this.

Read the detailed description

PRIMARY OBJECTIVE:

  • To estimate engraftment by day +42 post-transplant in patients who receive CD45RA-depleted haploidentical donor progenitor cell transplantation following reduced intensity conditioning regimen that includes haploidentical natural killer (NK) cells.

SECONDARY OBJECTIVES:

  • Estimate the incidence of malignant relapse, event-free survival, and overall survival at one-year post-transplantation.
  • Estimate incidence and severity of acute and chronic (GvHD).
  • Estimate the rate of transplant related mortality (TRM) in the first 100 days after transplantation.

Blood progenitor cells will be collected from adult donors to be used for transplantation. Donor cells will be processed and filtered in a laboratory at St. Jude using a machine called the CliniMACS™ device, and later infused (transplanted) into the participant through his/her veins.

Participants undergo a conditioning regimen beginning Day 21 prior to progenitor cell transplantation that includes chemotherapy medications and natural killer cells in preparation for transplantation. They will then receive T-cell depleted HPC transplant followed by CD45RA-depleted HPC transplant the following day.

Being tested
Cyclophosphamide, Fludarabine, G-CSF, Interleukin-2, Melphalan
Keywords
Hematological malignancies, Allogeneic hematopoietic cell transplant, Refractory hematologic malignancy, Relapsed hematologic malignancy
Medical subject headings
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Sarcoma, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myelomonocytic, Juvenile, Myelodysplastic Syndromes, Lymphoma, Non-Hodgkin, Hematologic Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CyclophosphamideDrug

    Also called Cytoxan

    Given intravenously (IV)

  • FludarabineDrug

    Also called Fludara, Fludarabine monophosphate

    Given IV

  • G-CSFBiological

    Also called Filgrastim, Neupogen®

    Given IV or subcutaneously (SQ)

  • Interleukin-2Biological

    Also called IL-2, Aldesleukin

    Given SQ

  • MelphalanDrug

    Also called L-phenylalanine mustard, Phenylalanine mustard, L-PAM, L-sarcolysin

    Given IV

  • ThiotepaDrug

    Also called ThioplexV, TESPA, TSPA

    Given IV

  • RituximabDrug

    Also called Rituxan™

    Given IV

  • Natural killer cell therapyBiological

    Also called NK cell therapy

    Given IV

  • T-cell depleted HPC transplantBiological

    Also called HPC,A Infusion(ɑ/β T cell depleted)

    T-cell depleted hematopoietic stem cells will be infused on day 0.

  • CD45RA-depleted HPC transplantBiological

    CD45RA depleted stem cells will be infused on day 1.

Study groups in NCT02259348
Study groupRoleWhat they receive
ParticipantsExperimentalParticipants undergo a conditioning regimen with cyclophosphamide, fludarabine, aldesleukin (interleukin-2), natural killer cell therapy, anti-thymocyte globulin, rituximab, thiotepa, and melphalan prior to transplantation of T-cell depleted HPC transplant on day 0 and CD45RA-depleted HPC transplant on day 1. Beginning Day 6 post-transplant, patients receive G-CSF daily until ANC recovers to normal level.
Receives: Drug: Cyclophosphamide; Drug: Fludarabine; Biological: G-CSF; Biological: Interleukin-2; Drug: Melphalan; Drug: Thiotepa; Drug: Rituximab; Biological: Natural killer cell therapy; Biological: T-cell depleted HPC transplant; Biological: CD45RA-depleted HPC transplant

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Engrafted by Day 42 Post-transplant

    To estimate engraftment by day +42 post-transplant in patients who receive CD45RA-depleted haploidentical donor progenitor cell transplantation following reduced intensity conditioning regimen that includes haploidentical NK cells. Engraftment is defined as the first of 3 consecutive tests performed on different days of an ANC ≥ 500/mm^3 with evidence of donor cell engraftment.

    Measured: Day 42 post transplantation

Secondary outcomes (6)

  1. Incidence of Malignant Relapse

    The estimate of cumulative incidence of relapse will be estimated using Kalbfleisch-Prentice method. Death is the competing risk event. The number of participants with incidence of malignant relapse is given. Relapse was evaluated using standard WHO criteria for each disease.

    Measured: one year post transplantation

  2. Event-free Survival (EFS)

    The Kaplan-Meier estimate of event-free survival (EFS) along with their standard errors will be calculated using the SAS macro (bmacro251-Excel2007\kme) available in the Department of Biostatistics at St. Jude, where EFS = min (date of last follow-up, date of relapse, date of graft failure, date of death due to any cause) - date of transplant, and all participants surviving at the time of analysis without events will be censored. The number of participants who did not experience any of these events through one year post-transplant is given.

    Measured: one year post transplantation

  3. Overall Survival (OS)

    The Kaplan-Meier estimate of OS along with their standard errors will be calculated using the SAS macro (bmacro251-Excel2007\kme) available in the Department of Biostatistics at St. Jude, where OS = min (date of last follow-up, date of death) - date of transplant and all participants surviving at the time of analysis without events will be censored. The number of participants surviving to one-year post-transplantation is given.

    Measured: one year post transplantation

  4. Incidence and Severity of Acute GvHD

    The cumulative incidence of acute GvHD will be estimated using Kalbfleisch-Prentice method. Death is the competing risk event. The severity of acute GvHD. The number of participants with incidence by grade is given. Participants are graded on a scale from 1 to 4, with 1 being mild and 4 being severe.

    Measured: 100 days post transplantation

  5. Incidence and Severity of Chronic GvHD

    The cumulative incidence of chronic GvHD will be estimated using Kalbfleisch-Prentice method. Death is the competing risk event. The severity of chronic GvHD will be described. Chronic GvHD was evaluated using NIH Consensus Global Severity Scoring." The number of participants with incidence by severity is given.

    Measured: one year post transplantation

  6. Rate of Transplant-related Mortality (TRM)

    The cumulative incidence of transplant related mortality will be estimated using Kalbfleisch-Prentice method. Deaths before day 100 because of other reasons are the competing risk events.

    Measured: 100 days post transplantation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Oct 2014 (estimated)
  2. Study startOct 2014
  3. Primary completionApr 2015
  4. Study completionMar 2016

Why it stopped: Investigator's decision.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
12 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02259348
Sponsor's protocol ID
REFNK1
Other IDs
NCI-2014-01925
Status last verified
Sep 2016
First submitted
3 Oct 2014
Last updated
30 May 2017
Data monitoring committee
No

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in